Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Merck
McKesson
Colorcon
McKinsey

Last Updated: January 26, 2020

DrugPatentWatch Database Preview

Patent: 9,180,214

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,180,214
Title:Gonadotropin-releasing hormone receptor-targeting peptides and their use to treat and diagnose cancer
Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image and treat cancers, especially cancers which overexpress GnRH such as breast cancer, prostate cancer and melanoma, among others, including metastatic breast cancer, prostate cancer and/or melanoma among numerous others in vivo. The novel imaging probes are capable of detecting cancerous cells, as well as their metastatic spread in tissues. The novel probes of the present invention will also be useful to initiate therapy for breast and/or prostate cancer, among other cancers, as well as monitor patients\' response to chemotherapy treatments and other interventions or therapies used in the treatment of cancer, including metastatic cancer as otherwise described herein. Compounds according to the present invention may be used as diagnostic tools for diagnosing cancer as well as therapeutic agents for treating cancer and related secondary disease states and conditions.
Inventor(s): Miao; Yubin (Albuquerque, NM)
Assignee: STC.UNM (Albuquerque, NM)
Application Number:13/447,918
Patent Claims:see list of patent claims

Details for Patent 9,180,214

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX Orphan search
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX Orphan search
Glaxo Grp Ltd ARZERRA ofatumumab INJECTABLE; INJECTION 125326 001 2009-10-26   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial STC.UNM (Albuquerque, NM) 2031-04-22 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
AstraZeneca
McKinsey
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.